The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...

Today, FMI President and CEO Leslie Sarasin issued the following statement: "Shoppers may be worried about their grocery needs due to the ongoing strike by the International Longshoremen's Association ...

For mesothelioma, combinations of Opdivo (nivolumab) and Yervoy (ipilimumab) may be part of the treatment plan if you're between stage 2 and stage 4 mesothelioma. The most critical way to prevent ...

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...